ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET

Corporate Participants

Al Kildani - Senior Vice President, Investor Relations and Corporate Communications
Steve Davis - President and Chief Executive Officer
Brendan Teehan - Chief Operating Officer, Head of Commercial
Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution
Mark Schneyer - Chief Financial Officer

Conference Call Participants

Tessa Romero - JPMorgan
Ritu Baral - TD Cowen
Gregory Renza - RBC Capital Markets
Ami Fadia - Needham & Company
Yatin Suneja - Guggenheim
David Hoang - Citigroup
Joel Beatty - Baird
Elaine Kim - Cantor
Jose Lora - Citizens JMP
Ash Verma - UBS
Marc Goodman - Leerink
Sumanth Kulkarni - Canaccord Genuity
Uy Ear - Mizuho

Operator

Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 Financial Results and Operating Overview Conference Call. At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Al-Kildani, Senior Vice President of Investor Relations and Corporate Communications. Please proceed.

Al Kildani

Thank you. Good afternoon and thank you for joining us on today's call to discuss ACADIA's first quarter 2024 earnings. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks, followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss our strong commercial franchises, DAYBUE and NUPLAZID.

Also joining us is Kimberly Manhard, Senior Vice President of Global Strategic Planning and Execution, who will provide an update on our pipeline program. And Mark Schneyer, our Chief Financial Officer, will review the financial highlights. Steve will then provide some closing thoughts before we open the call up for your questions. In addition, Parag Meswani, Senior Vice President, Trofinetide - Rare Disease Franchise, will be available for the Q&A session.

We are using supplemental slides, which are available on our website's events and presentation section. Before proceeding, I would like to remind you that during our call today, we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, or future results, are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date.